Skip to Content

Impavido Approval History

FDA Approved: Yes (First approved March 19, 2014)
Brand name: Impavido
Generic name: miltefosine
Dosage form: Capsules
Company: Paladin Labs Inc.
Treatment for: Leishmaniasis

Impavido (miltefosine) is an oral alkylphosphocholine antiparasitic for the treatment of leishmaniasis.

Development History and FDA Approval Process for Impavido

DateArticle
Mar 19, 2014Approval FDA Approves Impavido to Treat Tropical Disease Leishmaniasis
Nov 13, 2013Paladin Announces Extension of the Impavido PDUFA Date by Three Months

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide